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Amino acid substitutions V63I or 
A37S/I61T/V63I/V100A in the PA 
N-terminal domain increase the 
virulence of H7N7 influenza A virus
Meng Hu1, Hin Chu1, Ke Zhang1, Kailash Singh2, Cun Li1, Shuofeng Yuan1, Billy K. C. Chow2, 
Wenjun Song1, Jie Zhou1 & Bo-Jian Zheng1
The PA N-terminal domain (PA-Nter) is essential for viral transcription and replication. Here we 
identified PA-Nter substitutions A37S, I61T, V63I and V100A in recently emerged avian influenza A 
viruses (IAVs) with potential effect on virus pathogenicity and/or host adaptation. We introduced the 
identified PA-Nter substitutions into avian H7N7 IAV by reverse genetics. Our results showed that 
single substitution V63I and combined substitutions, I61T/V63I and A37S/I61T/V63I/V100A (Mfour), 
significantly increased virus growth capacity in mammalian cells. Meanwhile, these substitutions 
conferred higher virus transcription/replication capacity by producing more mRNA, cRNA and vRNA. 
Consistently, the polymerase activity and the endonuclease activity were enhanced by these PA-Nter 
substitutions. Notably, substitutions V63I and Mfour strongly increased virus replication and virulence 
in mice. Collectively, our findings demonstrated that the PA-Nter substitutions V63I and Mfour 
enhanced IAV pathogenicity through modification of the polymerase activity and the endonuclease 
activity, which added to the evolving knowledge of IAV virulence determinants.
In the past decades, more than ten different subtypes of avian influenza A viruses (IAVs) have overcome species 
barriers and transmitted to humans, posing great threats to the public health1. According to WHO reports, avian 
H5N1 IAV has caused 846 cases of human infections with 449 deaths since 20032. Avian H7N7 IAV caused 89 
cases of human infections with one death in the Netherlands in 20033. Apart from these infection cases, at least 
1,000 individuals were exposed to the avian H7N7 IAV during the outbreaks in the Netherlands and abroad dur-
ing 2003 and 20044. Additionally, the avian H7N7 IAV caused three other cases of human infections in Italy in 
20135. Moreover, several novel avian IAVs have emerged and infected humans in the past three years, including 
H7N96, H5N67 and H10N8 IAVs8,9. The recurrence of avian IAVs together with ongoing emergence of novel avian 
IAVs underscore the need for a better understanding on avian IAV pathogenicity.
The pathogenicity of avian IAVs are polygenic, being determined in part by the constellation of virus genes10. 
PA is a component of the IAV RNA polymerase complex that is essential for viral transcription and replica-
tion1. The N-terminal region of PA (PA-Nter, 1–197 amino acids) is a major functional domain that possesses 
protease activity11 and promoter binding activity12,13. Moreover, the PA-Nter domain functions as an endonu-
clease that snatches capped primers from host mRNAs for the initiation of virus mRNA transcription14,15. Hara 
et al. found PA-Nter substitutions D108A and K134A completely blocked the endonuclease activity11. Crepin 
et al. also confirmed a number of PA-Nter mutations (E80A, R84A, D108A, E119A, Y130A, K134A and K137A) 
that inhibited the endonuclease activity16. Additionally, recent studies have demonstrated that PA-Nter substi-
tutions may contribute to the high pathogenic phenotype of avian IAVs17–21, though the underlying molecular 
mechanisms are not completely understood. For example, the PA-Nter substitutions T85I and G186S have been 
reported to enhance the polymerase activity of A(H1N1)pdm09 IAV in vitro17. The PA-Nter T97I substitution 
increases the virulence of H5N2 IAV18 and contributes to mammalian adaptation of H5N1 IAV in mice19. The 
PA-Nter K142E has been shown to increase the pathogenicity of H5N1 IAV in vivo when combined with mutation 
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PB2-E627K20,21. Together, identification of virulence determinants in PA-Nter and the underlying mechanisms 
are required in order to fully understand the IAV pathogenicity.
In this study, we identified PA-Nter substitutions A37S, I61T, V63I and V100A in recently emerged avian IAVs 
with potential effect on virus pathogenicity and/or host adaptation by comprehensive bioinformatics analyses. 
To investigate the biological significance of these PA-Nter substitutions, we selectively generated mutant viruses 
of A/Netherlands/219/2003 (H7N7) harboring single or combined substitutions, I61T, V63I, I61T/V63I, A37S/
V100A and A37S/I61T/V63I/V100A (Mfour) by reverse genetics. Virus growth capacity, transcription/replica-
tion capacity, the polymerase activity and the endonuclease activity of these mutants were compared with those 
of the wild type in vitro. We further investigated the effect of the substitutions V63I and Mfour on virus replica-
tion and virulence in mice. Notably, we demonstrated that the PA-Nter substitutions, V63I or Mfour, conferred 
enhanced virus pathogenicity in vitro and in vivo. Our study may help to understand the pathogenicity of the 
emerging avian IAVs and other IAVs carrying these substitutions, which adds to the evolving knowledge of IAV 
virulence determinants and facilitates the assessment of pandemic risks.
Results
Identification of PA-Nter substitutions that may enhance virus pathogenicity and/or host adap-
tation. By sequence alignment and analyses, we identified amino acid variations at positions 37, 61, 63 and 
100 of PA-Nter among influenza A viruses (IAVs) from human infections (Table 1). We found that most IAV sub-
types presented 37 alanine (37A), 61 isoleucine (61I), 63 valine (63V) and 100 valine (100V) in PA-Nter. However, 
these residues were substituted to be 37 serine (37S), 61 threonine (61T) and 63 isoleucine (63I) in almost all 
the recently emerged avian IAVs, including H7N96,22, H5N6 in 20157,23, H10N88,9 and H9N2 since 201424 
(Table 1). Moreover, the majority of H7N9 and H5N6 IAVs isolated in 2015 possessed alanine (A) at position 
100. Thus, our data suggested that the PA-Nter substitutions A37S, I61T, V63I and V100A, singly or in combina-
tion, might confer avian IAV growth and/or adaptation advantages in humans. Moreover, we examined PA-Nter 
sequences of human isolates of avian H7N9 and avian H7N7, which showed high phylogenetic similarity with 
each other6. Our analysis showed that the PA-Nter of all the human H7N7 isolates harbored 37A/61I/63V/100V 
while ~90% of H7N9 isolates presented 37S/61T/63I/100A (Table 1). Further sequence inspection revealed that 
avian H7N7 IAV with PA-Nter 37S, 61T, 63I or 100A had already been detected in mammalian or avian species 
(Supplementary Table S1). In addition, the percentages of avian H7N7 isolates bearing these PA-Nter substitu-
tions increased in avian hosts since 2013 (Supplementary Table S1). On the basis of these findings, we speculated 
the PA-Nter substitutions at positions 37, 61, 63 and 100 might enhance IAV replication and pathogenicity, which 
could promote virus transmission to humans. Therefore, we were obliged to identify the biological significance of 
these PA-Nter substitutions in the background of avian H7N7 IAV.
Effect of substitutions on virus growth. As PA-Nter residues of H7N9 IAV differed from those of 
WT-H7N7 exclusively at positions 37, 61, 63 and 100, we first asked whether these four substitutions affected virus 
growth capacity. The plasmid-based reverse genetics of avian H7N7 IAV was established (Supplementary Fig. S1). 
Recombinant viruses WT-H7N7 and A37S/I61T/V63I/V100A (Mfour) were generated by reverse genetics 
(Supplementary Figs S2 and S3). To compare the growth capacity of the WT-H7N7 virus and the Mfour mutant 
virus, we inoculated the viruses into MDCK cells at a multiplicity of infection (MOI) of 1 and harvested superna-
tants at the indicated time points. As shown in Fig. 1A, viral titers of Mfour were 2.6-fold (P = 0.0159), 3.2-fold 
Subtypes
No. of 
isolates
The frequency of PA-Nter residues
37 61 63 100
S A T I I V A V
H7N9 400 100%a —b 99.50% 0.50% 100% — 89.50% 10.50%
H5N6 (in 2015) 1 100% — 100% — 100% — 100% —
H10N8 3 100% — 100% — 100% — — 100%
H9N2 (since 2014) 2 100% — 100% — 100% — — 100%
H7N2 1 — 100% — 100% 100% — — 100%
H7N3 2 — 100% — 100% 50% 50% — 100%
H7N7 7 — 100% — 100% — 100% — 100%
H5N1 384 — 100% 1.30% 98.44% 0.78% 91.93% — 87.56%
A(H1N1) pdm2009 4354c 0.02% 99.95% 0.03% 99.97% 0.18% 99.82% 5.88% 93.57%
H3N2 7221 — 100% 0.07% 99.65% 0.90% 99.04% 97.31% 2.31%
H1N2 39 — 100% — 97.44 2.56% 97.44% 79.49% 12.82%
H9N2 (before 2014) 9 — 100% — 100% — 100% — 100%
H6N1 1 — 100% — 100% — 100% — 100%
H5N6 (in 2014) 2 — 100% — 100% — — — 100%
Table 1.  The frequency of PA-Nter residues at positions 37, 61, 63 and 100 of influenza A viruses isolated 
from human infections. aThe percentage represents the frequency of the isolates possessing the indicated 
residues within each subtype. Full-length PA sequences of the isolates listed above were retrieved from the 
website Global Initiative on Sharing All Influenza Data (GISAID) (http://platform.gisaid.org) and analyzed in 
January 2016. b– represents none. cThe isolates were those uploaded to the website GISAID in 2009.
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(P = 0.0025) and 2.2-fold (P = 0.0286) higher than those of WT-H7N7 at 9, 12 and 24 hours post-infection (hpi), 
respectively. Therefore, the substitution Mfour (A37S/I61T/V63I/V100A) enhanced virus growth of avian H7N7 
IAV in mammalian cells.
Next, we generated additional mutant viruses to delineate the effect of PA-Nter substitutions. 
Recombinant viruses carrying the single substitutions I61T and V63I were obtained by reverse genetics 
(Supplementary Figs S2 and S3). As the effect of 37A and 100V on virus pathogenicity had been previously 
reported in the background of H7N9 IAV25, we did not investigate these two substitutions individually in this 
study. Considering the possibility that the PA-Nter substitutions might occur simultaneously, as shown in several 
IAV isolates in nature (Table 1 and Supplementary Table S1), we generated recombinant viruses bearing com-
bined substitutions, including I61T/V63I and A37S/V100A (Supplementary Figs S2 and S3).
To evaluate the impact of the substitutions on virus growth, we inoculated recombinant viruses into MDCK 
cells at an MOI of 1 and harvested supernatants at 8 hpi. As shown in Fig. 1B, titers of the mutant viruses V63I, 
I61T/V63I and Mfour were substantially higher than that of WT-H7N7 (P < 0.05), whereas the titer of the A37S/
V100A mutant virus was lower than that of WT-H7N7 (P < 0.001). At the same time, the titer of the I61T mutant 
virus was not statistically different from that of WT-H7N7. Thus, our data indicated that V63I might be able to 
override the effect of suppressive residue(s) and play a predominant role in determining the virus growth capacity. 
Collectively, the PA-Nter substitutions V63I, I61T/V63I and Mfour (A37S/I61T/V63I/V100A) increased virus 
growth capacity in mammalian cells, whereas the substitution A37S/V100A posed a decreased effect.
Effect of substitutions on the synthesis of viral mRNA, cRNA and vRNA. Virus mRNA, cRNA and 
vRNA were synthesized during viral transcription and replication processes26. The PA-Nter plays essential roles 
in viral transcription and replication11–14. To further investigate the effect of the PA-Nter substitutions I61T, V63I, 
I61T/V63I, A37S/V100A and Mfour (A37S/I61T/V63I/V100A) on viral transcription and replication, we utilized 
the abundance of virus mRNA, cRNA and vRNA as indicators. The viruses were inoculated into MDCK cells at an 
MOI of 2 and cell lysates were harvested at 4 and 6 hpi. Our results showed that the V63I, I61T/V63I and Mfour 
mutant viruses produced significantly higher levels of mRNA (Fig. 2A), cRNA (Fig. 2B) and vRNA (Fig. 2C) than 
those of WT-H7N7 at 4 and 6 hpi (P < 0.05). Among these substitutions, V63I resulted in the highest amount of 
mRNA, cRNA and vRNA at 6 hpi (Fig. 2). In contrast, the A37S/V100A mutant virus produced a significantly 
lower amount of mRNA, cRNA and vRNA than WT-H7N7 at 4 and 6 hpi (P < 0.05) (Fig. 2). The I61T mutant 
virus produced slightly reduced levels of mRNA (P = 0.0120), cRNA (P = 0.0378) and vRNA (P < 0.001) when 
compared with those of WT-H7N7 at 4 hpi (Fig. 2). Taken together, these results suggested that V63I alone and 
the combined substitutions I61T/V63I and Mfour (A37S/I61T/V63I/V100A) increased viral transcription and 
replication by producing more mRNA, cRNA and vRNA in mammalian cells.
Figure 1. Comparison of virus growth in MDCK cells. (A) MDCK cells were infected with WT-H7N7 and 
A37S/I61T/V63I/V100A (Mfour) viruses at a multiplicity of infection (MOI) of 1. Cell culture supernatants 
were collected at 6, 9, 12 and 24 hours post-infection (hpi) for virus titration in MDCK cells by plaque assay. 
Results shown are means ± standard deviation (SD) of independent experiments performed at least three times. 
* and ** represent P < 0.05 and P < 0.01, respectively, according to two-tailed Student’s t-test compared to 
that of WT-H7N7. (B) MDCK cells were infected with WT-H7N7 and mutant viruses I61T, V63I, I61T/V63I, 
A37S/V100A and Mfour at an MOI of 1. Cell culture supernatants were collected at 8 hpi for virus titration. 
Experiments were independently performed at least three times. Data presented are the percentages of viral 
titers of the indicated mutant viruses relative to that of WT-H7N7 (means ± SD). *** represents P < 0.001, 
according to a one-way ANOVA followed by a Dunnett’s test.
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Effect of substitutions on the polymerase activity. The polymerase complex, composed of PA, PB1 
and PB2, together with NP, are responsible for viral transcription and replication26. Minireplicon assays were 
performed to evaluate the impact of the PA-Nter substitutions I61T, V63I, I61T/V63I, A37S/V100A and Mfour 
(A37S/I61T/V63I/V100A) on the polymerase activity in human 293-T cells. Our data showed that the polymer-
ase complex carrying V63I and the combined substitutions I61T/V63I and Mfour significantly increased the 
polymerase activity compared to that of WT-H7N7 (P < 0.001) (Fig. 3). In contrast, A37S/V100A substantially 
decreased the polymerase activity when compared to that of WT-H7N7 (P < 0.001) (Fig. 3). Hence, the PA-Nter 
substitutions V63I alone and the combined substitutions (I61T/V63I and Mfour) imposed higher polymerase 
activity in human cells.
Effect of substitutions on the endonuclease activity. The PA-Nter functions as an endonuclease that 
cleaves 10–13 nucleotides from host pre-mRNAs, thereby snatching primers for virus mRNA transcription14,15. 
To investigate whether the PA-Nter substitutions I61T, V63I, I61T/V63I, A37S/V100A and Mfour (A37S/I61T/
V63I/V100A) affect the endonuclease activity, we cloned the virus PA-Nters (with and without these substitu-
tions) into pET-32a (+ ) expression vector (Supplementary Fig. S4) and expressed PA-Nter proteins in E. coli. 
Purified PA-Nter proteins were obtained in the second eluates (E2) (Fig. 4A and 4B) and used for the subsequent 
fluorescence-based endonuclease assays. As shown in Fig. 4C, the WT-H7N7 PA-Nter protein retained the endo-
nuclease activity when expressed in E. coli. We then compared the endonuclease activity of PA-Nter proteins 
of WT-H7N7 and mutants. The result showed that the PA-Nter proteins of the substitutions V63I, I61T/V63I 
and Mfour exhibited significantly higher endonuclease activity than that of WT-H7N7 (P < 0.05), whereas the 
PA-Nter I61T protein showed lower endonuclease activity than that of WT-H7N7 (P = 0.0119) when compared to 
that of WT-H7N7 (Fig. 4D). Thus, the substitution V63I alone and combined substitutions I61T/V63I and Mfour, 
significantly enhanced the PA-Nter endonuclease activity, thereby increasing viral transcription and subsequent 
replication.
Effect of substitutions V63I and Mfour (A37S/I61T/V63I/V100A) on viral pathogenicity in mice. 
As demonstrated above, the PA-Nter substitution Mfour (A37S/I61T/V63I/V100A) was prevalent in the majority 
of recently emerged IAVs, which increased the virus growth and transcription/replication capacity in vitro. At the 
same time, V63I was indicated to pose a dominant effect on enhancing the virulence among the tested substitu-
tions. Thus, we next selectively investigated the effect of these two substitutions on virus pathogenicity in vivo. 
Figure 2. Quantification of viral mRNA, cRNA and vRNA. MDCK cells were infected by WT-H7N7 and 
mutant viruses I61T, V63I, I61T/V63I, A37S/V100A and Mfour at an MOI of 2. Cell lysates were harvested at 
4 and 6 hpi. Viral mRNA, cRNA and vRNA were extracted and quantified. Experiments were independently 
performed three times. Viral mRNA, cRNA and vRNA were quantified and normalized with that of cellular 
GAPDH mRNA (means ± SD).
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BALB/c mice were intranasally inoculated with WT-H7N7, V63I mutant virus, Mfour mutant virus or PBS. As 
shown in Fig. 5A, mice infected with the V63I and Mfour mutant viruses showed significantly more severe body 
weight loss than that of WT-H7N7 infected mice. Correspondingly, the survival rate of V63I and Mfour mice 
were significantly lower than that of WT-H7N7 mice (P < 0.01). All the V63I and Mfour mice succumbed to the 
infection by day 9 while 20% of the WT-H7N7 mice survived the infection (Fig. 5B). Moreover, the V63I mice 
showed higher viral titers in lung tissues on days 3 and 5 post-infection (P < 0.05), while the Mfour exhibited sig-
nificantly higher lung viral titers on day 5 post-infection (P = 0.0065) (Fig. 5C). Thus, we demonstrated that the 
PA-Nter substitutions V63I and Mfour enhanced virus growth and pathogenicity in vivo.
Effect of substitutions on the PA-Nter structure. The 3D models of WT-H7N7 and Mfour (A37S/
I61T/V63I/V100A) PA-Nters were generated and validated. Molecular docking was performed to identify the 
potential differences between the PA-Nter structures of WT-H7N7 and Mfour. As shown in Fig. 6, the Δ G value 
of Mfour was substantially lower than that of WT-H7N7, suggesting an increased affinity of the PA-Nter towards 
the same ligand molecule. The 3D structural differences of WT-H7N7 and Mfour PA-Nter models were showed 
in Fig. 6 and Supplementary Table S2. Interestingly, the Mfour PA-Nter model used a different table (3hw6) with 
a QMEAN 4 of − 5.46, whereas the WT-H7N7 PA-Nter model best aligned with 3hw4 with a QMEAN 4 of − 2.41 
(Supplementary Table S2). Collectively, the PA-Nter model of Mfour showed substantial differences from those of 
WT-H7N7 in both 3D structure and affinity towards the ligand molecule.
Discussion
In this study, we identified PA-Nter substitutions at positions 37, 61, 63 and 100 in the recently emerged avian 
influenza A viruses (IAVs) that played key roles in promoting virus replication and might facilitate virus trans-
mission to human hosts. We found that the PA-Nter substitution V63I alone and combined substitutions, I61T/
V63I and Mfour (A37S/I61T/V63I/V100A), enhanced virus growth capacity when compared to that of wild type 
avian H7N7 IAV in mammalian cells. At the same time, these substitutions potentiated viral transcription and 
replication by producing more virus mRNA, cRNA and vRNA in infected cells. Furthermore, the polymerase 
activity and the endonuclease activity were augmented by these PA-Nter substitutions. Notably, the V63I and 
Mfour substitutions enhanced virus growth and virulence in mice. Collectively, our data demonstrated that the 
substitution V63I alone and the combined substitution Mfour (A37S/I61T/V63I/V100A) increased viral patho-
genicity of avian H7N7 IAV through modification of the polymerase activity and the endonuclease activity.
Genetic determinants in virus genes (i.e. HA27, NA28, PB229, PB1-F230, NEP31 and NS32) have been reported to 
contribute to increased pathogenicity and/or adaptation in human or mammalian hosts. Despite these extensive 
studies, the molecular determinants for IAV virulence and cross-species adaptation in humans remain incom-
pletely understood33. Previous studies have identified substitutions in PA enhanced the virulence of IAVs18,34–37. 
Interestingly, the majority of PA virulence determinants were found to cluster in PA-Nter, suggesting a critical 
role of PA-Nter in IAV pathogenicity. In this study we characterized the effect of PA-Nter substitutions I61T, 
V63I, I61T/V63I, A37S/V100A and Mfour (A37S/I61T/V63I/V100A) on virus pathogenicity in the context of 
Figure 3. Comparison of the polymerase activity in 293-T cells. 293-T cells were transfected with the 
plasmids pHW2000-PB1, -PB2, -NP and -PA (with and without the substitutions), together with a plasmid 
encoding firefly luciferase reporter flanked by IAV untranslated region as well as a plasmid encoding eGFP 
as an internal control. Luciferase activity was determined at 24 hours post transfection. Experiments were 
independently performed three times. Data presented are the relative polymerase activity of the indicated 
mutants to that of WT-H7N7 (means ± SD).
www.nature.com/scientificreports/
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avian H7N7 IAV. Importantly, the Mfour and V63I substitutions were identified as virulence determinants, which 
added to the evolving knowledge of IAV pathogenicity and benefited the surveillance of IAVs.
We identified PA-Nter substitutions at positions 37, 61, 63 and 100 in recently emerged IAVs, including the 
majority of H7N9 and H5N6 IAVs isolated in 2015. Avian H7N9 IAV has caused a large number of severe human 
infections in China since 20136. The virus is a reassortant with six internal genes derived from H9N2 IAV38. 
Interestingly, we found that the majority of avian H7N9 IAV presented PA-Nter 37S/61T/63I/100A whereas avian 
H9N2 IAV isolated before 2014 harbored 37A/61I/63V/100V. As H7N9 IAV is considerably more pathogenic 
than avian H9N2 IAV in humans22,39, the substitution A37S/I61T/V63I/V100A may be one of the contributing 
factors that account for the higher pathogenicity. Note that human H9N2 isolates during 2014 and 2015 present 
the PA-Nter substitution 37S/61T/63I/100V, which may suggest that the H9N2 IAV is continuously evolving and 
posing a pandemic potential to humans.
Virus mRNA transcription is primer-dependent, which requires caps snatched from the host cells in the ini-
tiation step26. The “cap-snatching” is carried out by the endonuclease activity of viral polymerase26. The PA-Nter 
endonuclease domain (residues 1–197) has not been identified until recent years11,14,15. However, key active sites 
that may determine PA-Nter endonuclease activity have not been fully understood. In this study we determined 
the substitutions, including I61T, V63I, I61T/V63I and Mfour, contributed to variations in the PA-Nter endo-
nuclease activity in the absence of the rest of the polymerase complex. Inspection of the crystal structure reveals 
that PA-Nter is a member of the PD-(D/E)XK superfamily, which utilizes divalent metal ions for nucleic acid 
cleavage14. Crepin et al. introduced mutations into the PA-Nter domain that inactivated the endonuclease activity 
and showed that these mutations might be involved in the positioning of RNA substrates in the endonuclease 
Figure 4. Comparison of the endonuclease activity of virus PA-Nter proteins expressed in E. coli. Virus PA-
Nter proteins were expressed in E. coli, purified, and identified by SDS-PAGE and Western blot using Anti-His 
antibodies. After concentrated and quantified, the PA-Nter proteins were then incubated with DNA substrates, 
which contained FAM and BHQ conjugated to the 5′ and 3′ ends, respectively. Fluorescence signals were 
released and measured at the indicated time points. The purified protein from unmodified vector was achieved 
and used as a negative control. (A) The Coomassie-stained SDS-PAGE image and Western blot result of WT-
H7N7 PA-Nter and negative control protein (Vector). CL, cell lysates; FT, flow-through (wash fractions); E1, 1st 
eluates; and E2, 2nd eluates. E2 proteins were concentrated and used for the endonuclease assay. (B) Western 
blot result of purified PA-Nter proteins of the indicated mutants. (C) Endonuclease assay of the WT-H7N7 
PA-Nter protein. Data represented are means ± SD of independent experiments performed at least three times. 
(D) Comparison of the endonuclease activity of the PA-Nter proteins of WT-H7N7 and the indicated mutants. 
Fluorescence signals were collected at 32 minutes after incubation. The experiments were independently 
performed at least three times. Results presented are the relative endonuclease activity of PA-Nter proteins of 
the indicated mutants to that of WT-H7N7 (means ± SD).
www.nature.com/scientificreports/
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Figure 5. Comparison of viral pathogenicity of WT-H7N7 and mutant viruses V63I and Mfour in mice. 
Six to eight-week-old BLAB/c mice were intranasally inoculated with 120 PFU of the indicated viruses or PBS. 
(A) Mouse body weight was monitored daily for up to 14 days. The mice that lost more than 20% of their initial 
weight were humanely euthanized. Data shown represents the average body weight changes (means ± SD). 
(B) Survival rates of the mice were also recorded. ** represented P < 0.01, according to the Log-rank test 
when compared to that of WT-H7N7 virus. (C) Three mice in the indicated groups were euthanized and lung 
tissues were excised on days 3 and 5 post-infection. The lung virus titers were determined by plaque assay 
(means ± SD).
Figure 6. Comparison of the PA-Nter models of WT-H7N7 and Mfour. The 3D PA-Nter models of WT-
H7N7 and Mfour were generated and docked with Mn2+ ions (indicated by light blue ball) and an ssDNA 
substrate, respectively. Δ G values were calculated to obtain affinity of the PA-Nter models of WT-H7N7 and 
Mfour towards the ligand molecules. Differences in WT-H7N7 and Mfour PA-Nter models were aligned with a 
QMEAN 4 and scored.
www.nature.com/scientificreports/
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active site16. Likewise, PA-Nter substitutions (I61T, V63I, I61T/V63I and Mfour) may directly or indirectly affect 
the binding and/or positioning of the divalent metal ions and DNA/RNA substrates, thereby altering the endo-
nuclease activity. Further studies are required to clarify this issue. Additionally, the PA-Nter protein with the 
Mfour substitution showed the highest endonuclease activity among all the mutants in the endonuclease assay, 
yet the substitution did not contribute to the highest virus growth capacity and pathogenicity in vitro and in vivo. 
This observation can be reconciled with the potential structural changes of the expressed PA-Nter domain, the 
involvement of the rest of the polymerase complex in viral transcription and replication, or the direct or indirect 
interactions of these substitutions with specific host cellular factors40. Overall, our data add novel insights into the 
understanding on the PA-Nter endonuclease domain.
Moreover, the flexible loop region of PA-Nter (residues 53–73) is typically in a disordered structure and its 
function has been poorly understood41. In this study, we demonstrated that the V63I substitution at the flexible 
loop region of PA-Nter significantly increased the polymerase activity and the endonuclease activity whereas I61T 
posed a slightly decreased effect. Remarkably, all V63I-containing substitutions that we investigated in this study 
conferred higher polymerase activity and endonuclease activity. In this case, V63I may act as a dominant substi-
tution when co-exist with other suppressive substitutions including I61T and A37S/V100A. As PA-Nter has been 
demonstrated to be multifunctional in viral transcription and replication, including endonuclease activity, pro-
tein stability, cap binding and virus RNA promoter binding11, the V63I substitution may enhance the polymer-
ase activity through interacting with PB1, virus cRNA or vRNA promoters, or the host cellular factors. Desmet 
et al. demonstrated that residues at the PA-Nter flexible loop region suppressed cellular protein synthesis42. It 
is possible that the V63I may contribute to the inhibition of host protein synthesis and thereby increasing virus 
replication and pathogenicity. With undetermined structure of the flexible loop region41, how V63I interacts the 
rest of the polymerase subunits or other factors remain to be studied.
Yamayoshi et al. reported that PA-Nter substitutions S37A and A100V slightly enhanced the virulence of avian 
H7N9 IAV in mice, though the differences were not statistically significant25. In the present study, we further 
demonstrated PA-Nter combined substitution, A37S/V100A, substantially attenuated virus growth and transcrip-
tion/replication in vitro through decreasing the polymerase activity in avian H7N7 IAV. However, combined with 
the other two PA-Nter substitutions, the A37S/I61T/V63I/V100A increased the virus pathogenicity in vitro and 
in vivo. These findings indicate that the PA-Nter substitution A37S/I61T/V63I/V100A presented by the recently 
emerged IAVs contributes to an enhanced pathogenicity, though certain residues may pose an attenuated effect.
In conclusion, we demonstrated that the PA-Nter substitutions V63I and Mfour (A37S/I61T/V63I/V100A) 
increased virus growth capacity and pathogenicity in vitro and in vivo. The identification of these substitutions 
as pathogenic and human adaptation determinants may add to the current mutational analysis of the role of PA 
and aid in the assessment of pandemic potential of avian H7N7 IAV as well as other IAV subtypes carrying these 
substitutions in humans.
Methods
Cells and viruses. Madin-Darby canine kidney (MDCK) cells were grown in Eagle’s minimum essential 
medium (MEM, Life technologies) supplemented with 10% fetal bovine serum (FBS, life technologies) and 1% 
penicillin/streptomycin (P/S) at 37 °C with 5% CO2. Human embryonic kidney (HEK) 293-T cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM, Life technologies) supplemented with 10% FBS and 1% P/S. 
Avian influenza A virus (IAV) strain A/Netherlands/219/2003 (H7N7) (WT-H7N7) and mutant viruses were 
cultured in MDCK cells supplemented with 1% P/S43. All virus experiments were conducted in the biosafety level 
3 (BSL-3) laboratories44.
Sequence alignment and analyses. Full-length PA protein sequences of various IAV subtypes isolated 
from human infections were retrieved from the website Global Initiative on Sharing All Influenza Data (GISAID) 
(http://platform.gisaid.org) (isolate IDs available on request). Multiple sequence alignments were performed 
using the MEGA 6.06 software. The residues in the PA N-terminal domain (PA-Nter, 1–197 amino acids) were 
inspected and analyzed among different subtypes to identify the varied ones that might associate with virus 
pathogenicity.
Plasmid-based reverse genetics. The eight gene segments of avian IAV strain A/Netherlands/219/2003 
(H7N7) were cloned into expression vector pHW2000, respectively45. Recombinant viruses were generated by 
the established reverse genetics45. Briefly, virus RNAs of avian IAV strain A/Netherlands/219/2003 (H7N7) were 
extracted from supernatants of infected MDCK cells using QIAamp Viral RNA Mini Kit (Qiagen). Full-length 
virus cDNAs were amplified using two-step RT-PCR (primer sequences available upon request). The amplicons 
were firstly cloned into TA vector using TOPO TA Cloning Kit (Life Technologies) and subsequently transferred 
into the vector pHW2000. All constructs were confirmed by sequencing.
Site-directed mutagenesis. PA-Nter substitutions were introduced into plasmid pHW2000-PA 
(WT-H7N7) using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies).
Plasmid transfection and virus rescue. The eight plasmids possessing virus gene segments were mixed 
with ScreenFect A transfection reagent (InCella) according to the manufacture’s protocol and then added into 
the co-cultured 293-T and MDCK cells in the 12-well plates. The medium was replaced with Opti-MEM (Life 
technologies) supplemented with 1% P/S at 6 hours post transfection. The transfected cells were cultured at 37 °C 
for four days to rescue WT-H7N7 and mutant viruses. The viruses rescued were verified by sequencing.
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Virus growth assay. Growth capacity of WT-H7N7 and mutant viruses were investigated. Briefly, the 
viruses were inoculated into MDCK cells at a multiplicity of infection (MOI) of 1. Cell-free supernatants were 
harvested at the indicated time points and titrated in MDCK cells by plaque assay46.
Viral mRNA, cRNA and vRNA quantification. A two-step RT-qPCR assay was performed to quantify 
the abundance of viral mRNA, cRNA and vRNA, which would reflect viral transcription and replication capacity, 
as reported by Kawakami et al.47 and Cline et al.48, with modifications. Briefly, the viruses were inoculated into 
MDCK cells in 24-well plates at an MOI of 2. The infected cells were collected at 4 and 6 hours post-infection 
(hpi). Total virus RNAs were extracted using the RNeasy Mini Kit (Qiagen). By using Transcriptor First Strand 
cDNA Synthesis Kit (Roche), virus cDNAs were synthesized by using primers containing specific genetic tags 
for viral HA mRNA, HA cRNA and HA vRNA (primer sequences available on request). The cDNA of cellular 
GAPDH mRNA was synthesized as an internal control.
Real time qPCR was carried out on the LightCycler® 96 (Roche) machine. The primers targeting at the spe-
cific tags added in the cDNAs were utilized (primer sequences available on request). Briefly, 5 μ l of a 1:10 diluted 
cDNAs were mixed with 10 μ l of 2 × FastStart SYBR Green I Master (Roche), 1 μ l of forward primers (10 μ M), 
1 μ l of reverse primers (10 μ M) and 3 μ l of sterile water. Virus RNA levels were normalized with GAPDH mRNA 
level49.
Minireplicon assay. The polymerase activity of WT-H7N7 and mutants were investigated as previously 
described50. Briefly, 50 ng each of plasmids pHW2000-PB1, pHW2000-PB2, pHW2000-NP and the indicated 
pHW2000-PA, together with 50 ng plasmid encoding firefly luciferase reporter flanked by the IAV untrans-
lated region and 100 ng plasmid encoding eGFP, were transfected into 293-T cells cultured in 24-well plates 
using Lipofectamine® 3000 Transfection Reagent (Invitrogen). The cell lysates were harvested at 24 hours post 
transfection. Luciferase activity was measured on a Victor X3 multilabel plate reader (Perkin Elmer) by using 
Bright-Glo™ Luciferase Assay System (Promega). Fluorescence signals were also detected as an internal control 
for the transfection efficiency. The luciferase readings were normalized with the fluorescence readings.
Cloning and expression of virus PA-Nter proteins. The DNA fragments of PA-Nter (residues 1–196) 
were amplified from pHW2000-PA plasmids (with or without the substitutions) and cloned into pET-32a (+ ) 
expression vector containing a His6-tag (Novagen). The resulted plasmids were then transformed into E. coli  
strain BL21 (DE3) for protein expression50,51. Briefly, the bacteria were grown to an optical density of 
~ 0.7 at 600 nm (OD600) in LB medium with 100 μ g/ml ampicillin at 37 °C. After induction with 0.2 mM 
isopropyl-β -D-thio-galactopyranoside (IPTG), PA-Nter proteins were expressed by maintaining at 16 °C over-
night. The cells were harvested by centrifugation, re-suspended in the lysis buffer (50 mM HEPES, 300 mM NaCl, 
and 20 mM imidazole, pH 7.8) and sonicated for the release of soluble proteins. After removal of cell debris, 
PA-Nter proteins were purified using the Ni-NTA Agarose (Qiagen) with the linear gradient of imidazole solu-
tions for washing and elution (the concentration ranged from 20 mM to 250 mM). Unmodified vector was also 
transformed into E. coli, expressed, purified and used as the negative control. Purified proteins were confirmed 
by 10% SDS-PAGE gel and Western blot44. Finally, the proteins were concentrated by using Amicon Ultra-15 
Centrifugal Filters (Millipore).
Fluorescence-based endonuclease assay. Purified PA-Nter proteins were quantified using the 
Pierce™ BCA Protein Assay Kit (Thermo Scientific). Fluorescence-based endonuclease assay was performed as 
described previously50,52. Briefly, 0.2 μ g of PA-Nter proteins were incubated with DNA substrates (5′ FAM™ - 
TCTCTAGCAGTGGCGCC-3′ BHQ) in a reaction buffer (50 mM HEPES, 150 mM NaCl and 1 mM MnCl2, pH 
7.8) at 37 °C. Fluorescence signals were released after the cleavage of the DNA substrates by the PA-Nter proteins. 
The fluorescence signals were measured at the indicated time points on the Victor™ X3 multilabel plate reader 
(Perkin Elmer).
Virus infection in mice. Six to eight-week-old female BALB/c mice (11 mice/group) were anesthetized by 
intraperitoneal injection of ketamine-xylazine (50/5 mg/kg) and intranasally inoculated with 120 plaque-forming 
units (PFU) of the indicated viruses in a volume of 20 μ l. Five BALB/c mice were anesthetized and intranasally 
inoculated with 20 μ l of PBS as a negative control. Mouse body weight and survival were monitored daily for up 
to 14 days. The mice that lost more than 20% of their initial body weight were humanely euthanized. To evaluate 
virus replication in mice, 3 mice in each group were euthanized on days 3 and 5 post-infection and mouse lungs 
were excised. Lung tissues were homogenized in MEM medium and virus titers in the supernatants were titrated 
in MDCK cells by plaque assay44,53. All mouse experiments were conducted in accordance with the standard 
operating procedures of the approved biosafety level 3 animal facilities and were approved by the Committee on 
the Use of Live Animals in Teaching and Research of the University of Hong Kong.
Structure analysis. The 3D models of WT-H7N7 and Mfour PA-Nter were prepared by Swiss Model 
algorithm54. Based on the QMEAN score provided by the swiss model server, the best model was selected for 
further analysis. All the ligand molecules and ions were removed from the PDB files of the models by PDB edi-
tor. Furthermore, all the 3D models were structurally validated by SAVES server (http://services.mbi.ucla.edu/
SAVES/) with PROCHEK55 and the Ramachandran plot was analyzed by using RAMPAGE server54. Furthermore, 
the global sequence alignment was calculated by ALIGN (http://xylian.igh.cnrs.fr/bin/align-guess.cgi) with the 
template sequences. As PA-Nter proteins retained the endonuclease activity with Mn2+ ions14, all the models were 
docked with Mn2+ ions, PDB files of which were retrieved from 4E5G (the PDB structure file was retrieved from 
RCSB data bank) using PDB editor. The PA-Nter models of WT-H7N7 and Mfour were then docked with Mn2+ 
ions at the active sites of receptor by using patchdock algorithm56. Afterwards, the protein models in complex with 
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Mn2+ ions were docked with 3D model of a single-stranded DNA sequence (5′ -TCTCTAGCAGTGGCGCC-3′), 
which was experimentally proved to be a substrate of the enzyme52 and used in our study. The DNA model was 
built using make-na server (http://structure.usc.edu/make-na/server.html)57. The docking was performed using 
Patchdock/firedock algorthim56,58. The final docking models after firedock refinement were used to collect Δ G 
values. Moreover, to evaluate the differences in the PA-Nter proteins of the WT-H7N7 and Mfour, the generated 
models were compared and aligned with a QMEAN 4, which had the scoring function for the identification of 
the best model59.
Statistical analysis. Two-tailed Student’s t-test, or one-way ANOVA followed with a Dunnett’s test, or 
Log-rank (Mantel-Cox) test with the GraphPad Prism 6 software package (GraphPad Software, La Jolla California 
USA) were used for data analysis. P < 0.05 was considered significantly different.
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